Weaning from invasive ventilation with levosimendan (WEANLESS): study protocol for a multicentre randomised clinical trial.
Esther De Leijer, Charlotte Hofma, Ary Serpa Neto...
https://pubmed.ncbi.nlm.nih.gov/42161542/Actively Recruiting
Led by Radboud University Medical Center · Updated on 2026-01-09
250
Participants Needed
8
Research Sites
52 weeks
Total Duration
Researchers are evaluating the use of levosimendan to help patients in intensive care units who are having difficulty stopping mechanical ventilation. The study focuses on adults who have been on a ventilator for more than 48 hours and failed at least one attempt to breathe on their own. The trial aims to see if levosimendan can improve diaphragm function and shorten the time patients need mechanical ventilation compared to a placebo. Participants will be randomly assigned to receive either levosimendan or a placebo called Soluvit, both given as a continuous intravenous infusion over 24 hours. The starting dose is 0.1 gkgmin, which may increase to 0.2 gkgmin after 4 hours if tolerated. If weaning from ventilation is not successful within 7 days, up to four treatment cycles may be given. All patients continue to receive standard ICU care with daily assessments for readiness to wean. During the study, researchers will collect data from medical records and routine monitoring without extra invasive procedures. They will assess ventilator-free days up to 28 days after randomization as the main outcome, along with other measures like ventilator-free days up to 90 days, dyspnea scores after extubation, reintubation rates, ICU and hospital length of stay, and mortality. Quality of life will be evaluated at baseline, 3 months, and 12 months. Safety monitoring includes heart rhythm, blood pressure, and adverse events related to the study drug.
CONDITIONS
Shorter Weaning From Invasive Ventilation With Levosimendan
E
Esther de Leijer, MD
L
Leo Heunks, MD, PhD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Radboud University Medical Center
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 28 days
Participants receive a 24-hour intravenous infusion of either levosimendan or placebo. Up to four treatment cycles may be given if weaning from mechanical ventilation is not successful within 7 days. All participants continue to receive standard ICU care including daily assessments for readiness to wean from invasive ventilation.
Continuous infusion with daily ICU assessments
Duration - Up to 12 months
Participants are monitored for ventilator-free days, dyspnea scores until ICU discharge or day 28, and quality of life is assessed at baseline, 3 months, and 12 months after inclusion.
Assessments at baseline, 3 months, and 12 months; daily symptom recording until ICU discharge or day 28
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Esther De Leijer, Charlotte Hofma, Ary Serpa Neto...
https://pubmed.ncbi.nlm.nih.gov/42161542/Radboud University Medical Center
Lead Sponsor